The High-Dose Aldesleukin (IL-2) SELECT Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatment in Patients with Advanced Melanoma

Patients eligible for treatment with high-dose interleukin-2 (LI-2) will submit tissue blocks from tumors of malignant melanoma for central review. Pretreatment blood will be drawn and sent to core laboratory for processing and storage. An optional pretreatment biopsy of an accessible tumor lesion will be performed in a subset of enrolled patients. Patients may receive IL-2 treatment up to a maximum of 3 courses.

Study Number: 

I 199411

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail